Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.
about
Activation and allosteric modulation of a muscarinic acetylcholine receptorSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersAn allosteric enhancer of M₄ muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaineStructure of the human M2 muscarinic acetylcholine receptor bound to an antagonistCaMKII hunkers down on the muscarinic M4 receptor to help curb cocaine-induced hyperlocomotionChemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAMA subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviorsA selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learningDiscovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRsCross-talk between bile acids and gastrointestinal tract for progression and development of cancer and its therapeutic implicationsMuscarinic acetylcholine receptor X-ray structures: potential implications for drug developmentA constitutively active G protein-coupled acetylcholine receptor regulates motility of larval Schistosoma mansoniStructure and dynamics of the M3 muscarinic acetylcholine receptorPtdIns4P synthesis by PI4KIIIα at the plasma membrane and its impact on plasma membrane identityDiscovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probeDiscovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatinsReflex control of immunityDevelopment of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Differential Muscarinic Modulation in the Olfactory BulbCholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's diseaseDiscovery of ML326: The first sub-micromolar, selective M5 PAMDiscovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375)Muscarinic agonists for the treatment of cognition in schizophreniaAnti-inflammation of spirocyclopiperazinium salt compound LXM-10 targeting α7 nAChR and M4 mAChR and inhibiting JAK2/STAT3 pathway in ratsThe antipsychotic potential of muscarinic allosteric modulationHistory of Chemistry in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.Knockouts reveal overlapping functions of M(2) and M(4) muscarinic receptors and evidence for a local glutamatergic circuit within the laterodorsal tegmental nucleus.Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaTargeting glutamate synapses in schizophreniaElimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspectsA novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learningMolecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic propertiesIncreased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice.Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia.
P2860
Q24308061-0B5B4F17-9F66-4D4D-A037-7E924178AF84Q24605472-28FE983E-A169-44A6-8C02-88E98669B618Q24608616-5F3D59C1-5053-4549-A940-69BE273D3E55Q24628686-27918711-C9F5-4DBF-8AE4-9CC8F9837434Q24628698-F16FE650-F894-4724-9A16-1EA9B0AD6D09Q24631627-BC837DDB-E518-4B8F-AD86-7867AE2545BBQ24645678-E772B316-5DF0-475D-AFBC-A37909CFB3FEQ24657785-6C8D4AC0-AC20-4666-890B-88E732966929Q24657902-0C166223-AA65-4AF8-A830-2D740FACACEEQ26752403-196767E8-EB87-4056-8FBC-6F4BF06E882FQ26801280-E43C8E2E-9950-4A8A-84B5-949B3F5D99F9Q26999429-C7007FE3-BEC2-453A-83FC-3240081AE462Q27308775-9B9684D8-CB4D-4B0E-B07C-8FEA12D20A92Q27677433-79F6F7FB-E90E-4BA9-9F2C-9068B8EE1E18Q28118990-24180081-2FFD-4710-A833-A869CA3F40CFQ28237300-9F0CD8C0-B0A6-4C35-93FD-B73066C6F966Q28244789-8DED9BCC-6583-4819-AA6B-88CF34E394E4Q28245909-512BDB65-087F-4036-8B83-C9CEA77DF80BQ28246512-5AF828C8-82A2-4B56-9B55-441E4C4A079FQ28265643-AF6774D7-F2D8-4CCA-BCAD-77759ED9B360Q28287090-5D47971D-5F67-4343-BE10-7350AD85DA2DQ28288485-259C2A11-AB53-41B1-AE2E-FBB8718D0549Q28300950-187E17A8-7796-438A-A1CD-3335B45E46DDQ28301970-D37DE37D-FDEA-41A6-8C45-CA56386717B0Q28534398-6460D8B7-F232-4DCB-BC7C-98F81131D1BFQ28603221-6ABDF6C0-21FC-4412-B58D-C27289BAAA9DQ30370827-ED2DFD6B-0A20-4900-B390-A9696D3B1842Q30388923-55CE8C98-A749-46A5-BD4C-00473018FE7CQ30447164-50A9FBEC-8A6B-486B-A80F-FBAF8E29AAFBQ30459624-DAC8BF73-4BA9-4DC2-AA8E-B67DC79A6AFFQ30460392-7288057D-6F61-4F6C-98DF-FCDA6BC95692Q30472919-5DEF00A4-73B0-4958-93DE-2F3CBFD40413Q30473410-317FF857-3F53-4E79-9948-36887D719D5DQ30474039-6CD55543-20D6-423E-8429-96CDC6CD5DAAQ30476813-A241C72D-D39B-40AC-9A1A-2B3A752C3AE6Q30488913-0D9DDF8C-5561-47C2-874B-DB82CC935D66Q30498538-D8EA1C3D-09BD-4314-A2BD-AD6E6ACD34A3Q30566770-907A3ECF-D99B-480A-9A8E-D748F9BEFC70Q33518105-EEBCE272-3F05-4472-A487-247E0E4A2E40Q33612122-98121AC0-BFE7-4F49-9B8F-218C141421DE
P2860
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Muscarinic acetylcholine recep ...... insights for drug development.
@en
type
label
Muscarinic acetylcholine recep ...... insights for drug development.
@en
prefLabel
Muscarinic acetylcholine recep ...... insights for drug development.
@en
P2093
P356
P1476
Muscarinic acetylcholine recep ...... insights for drug development.
@en
P2093
Dinesh Gautam
Jürgen Wess
Richard M Eglen
P2888
P304
P356
10.1038/NRD2379
P577
2007-09-01T00:00:00Z